An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Trial Status: active
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in
combination with toripalimab plus bevacizumab and to define a recommended dose for
casdozokitug in combination with toripalimab plus bevacizumab.
Inclusion Criteria
Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants.
Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies.
≥ 1 measurable lesion (per RECIST v1.1) that is untreated.
Exclusion Criteria
Has received prior systemic therapy for HCC.
Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.
Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
Has moderate or severe ascites.
Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Additional protocol-defined inclusion/exclusion criteria apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06679985.
